Novel drug delivery systems for steroidal hormones

Bibliography

• Therapeutic Drugs. Vol. 1, 2 & Suppl. Dollery C (Ed.), Churchill Livingstone, Edinburgh (1991).
   Google Scholar
• PAYNE R: Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semirr. Oncol. (1998) 25 (Suppl. 7):47–53.
   Google Scholar
• BLOOR K, LEESE B, MAYNARD A: The costs of managing severe cancer pain and potential savings from transdermal administration. Eur. j Cancer, Part A: General Topics (1994) 30:463–468.
   Google Scholar
• BURGER HG, HAILES J, MENELAUS M: The management of persistant symptoms with estradiol-testosterone implants clinical, lipid and hormonal results. Matimitas (1984):351–358.
   Google Scholar
• GOPFERICH A: Biodegradable polymers: polyanhydrides. In: Encyclopaedia of controlled drug delivery (Volume 1). Mathiowtz E (Ed.), John Wiley and Sons, New York, USA (1999):60–71.
   Google Scholar
• SANTOS CA: Fertility control. In: Encyclopaedia of controlled drug delivery (Volume 1). Mathiowtz E (Ed.), John Wiley and Sons, New York, USA (1999):364–381.
   Google Scholar
• ••A comprehensive overview over IUS andimplants.
   Google Scholar
• BEN-NUN I, SIEGAL A, SHULMAN A et al.: Induction of artificial endometrial cycles with oestradiol implants and injectable progesterone: establishment of a viable pregnancy in a woman with 17-a-hydroxylase deficiency. Human Reprod. (1995) 10(9):2456–2458.
   PubMed Web of Science ®Google Scholar
• SUHONEN SP, ALLONEN HO, LAHTEENMAKI P: Sustained release estradiol implants and a levonorgestrel releasing intrauterine device in hormone replacement therapy. Am. j Obstet. Gyn. (1995) 172(21):562–567.
   PubMed Web of Science ®Google Scholar
• SIEMINSKA L, BUNTER B, WOZNICAA, ZERDA TW: The use of sol-gel glass as a carrier for prolonged release of progesterone in the rat. Pharm. Sci. (1996) 2(12):567–568.
   Google Scholar
• COUTINHO EM: One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplanfl. Contraception (1993) 47:97–105.
   PubMed Web of Science ®Google Scholar
• PERALTA O, DIAZ S, CROXATTO H: Subdermal contraceptive implants.j Steroid Biochem. Ma. Biol. (1995) 53:223–226.
   PubMed Web of Science ®Google Scholar
• BRACHE V, MASSAI R, MISHELL DR JR. et al.: Ovarian function during use of Nestorone® subdermal implants. Contraception (2000) 61:199–204.
   Google Scholar
• COUTHINO EM, ATHAYDE C, DANTAS C, HIRSCH C, BARBOSA I: Use of a single implant of elcometrine (ST-1435) a nonorally active progestin as a long acting contraceptive for postpartum nursing women. Contraception (1999) 59:115–122.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB: Progestin implants. Steroids (2000) 65:681–685.
   PubMed Web of Science ®Google Scholar
• BENGHUZZI HA, ENGLAND BG: Long-term sustained delivery of androgens by means of TCPL devices and the effect on high-density lipoprotein in castrated rams. Biomed. Sci. Instrument. (1995) 31:165–170.
   PubMedGoogle Scholar
• LIT, LI B, CNI R, Song J, Song C, Jiang Y:Experimental studies on testosterone slow release drug delivery systems in vitro and in vivo. Chin. I Biomed. Engineer (1994) 13(3)222–225.
   Google Scholar
• GORDON E, LASSERRE A, STULL P, BAJPAI PK, ENGLAND B: A zinc based self setting ceramic bone substitute for local delivery of testosterone. Biomed. Sci. INSTRUMENT (1997) 33:131–136.
   PubMedGoogle Scholar
• ZAFIRAU W, BILLOTTE W PARKER C, BAJPAI PK: Development of a ceramic device for the continuos local delivery of steroids. Biomed. Sci. Instrument. (1996) 32:63–70.
   PubMedGoogle Scholar
• LASSERRE A, BAJPAI PK: Ceramic drug delivery devices. Grit Rev Ther. Drug Carrier Systems (1998) 15(1):1–56.
   PubMed Web of Science ®Google Scholar
• •A detailed overview over ceramic DDS.
   Google Scholar
• ZIEGENMEYER J: TTS: Transdermale Application von Arzneistoffen. Pharm. Ztg. (1989) 134:1516–1522.
   Google Scholar
• Mechanisms of transdermal drug delivery Potts PO, Guy RH. (Eds.), Marcel Dekker, Inc., New York, USA (1997):41–85.
   Google Scholar
• ••A basic reference in the area of transdermaldrug delivery.
   Google Scholar
• Physician's Desk Reference 2000, Medical Economics Company, Inc. Montvale, NJ, USA.
   Google Scholar
• SITRUK-WARE R: Progestins in the menopause. j Steroid Biochem. Mol Biol. (1999) 69:185–193.
   PubMed Web of Science ®Google Scholar
• ••A sound overview over the applications ofprogestins in the menopause.
   Google Scholar
• CAMERON ST, CRITCHLEY HOD, GLASIER AF, WILLIAMS AR, BAIRD DT: Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br Obstet. Cyr]. (1997) 104(10):1184–1190.
   PubMed Web of Science ®Google Scholar
• LIPP R: Selection and use of crystallisation inhibitors for matrix-type transdermal drug delivery systems containing sex steroids. Pharm. Pharmacol (1999)15:1343–1349.
   Google Scholar
• LAUGEL C, MARTY J-P: Pharmacocinetique des patchs delivrant des steroids. Rep. Humairre Hormones (1999) 12(4):399–402.
   Google Scholar
• AUDET M-C, MOREAU M, KOLTUN WD et al.: Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive. J Am. Med. Assoc. (2001) 285:2347–2354.
   PubMed Web of Science ®Google Scholar
• ROZENBAUM H, BIRKHAUSER M, DE NOOYER C etal.: Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy. Maturitas (1996) 25:161–173.
   Google Scholar
• DE SANCTIS V, VULLO C, URSO L et al.: Clinical experience using the AndrodermCr" testosterone transdermal system in hypogonadal adolescents and young men with P-thalassemia major. Pediat. Endocrin. Metall. (1998) 11\(Suppl. 3):891–900.
   Google Scholar
• ACBAY O, GONEN MS, KADIOGLU P, GUNDOGDU S: The effects of testosterone replacement on serum lipids and body composition in young men with hypogonadism. Klinik Celisim (1996) 9:4013–4018.
   Google Scholar
• HAFIDI A, GHARBI MH: Androgens and male sexuality. Andrologia (1996) 6:387–397.
   Google Scholar
• •A versatile review on the applications of androgens.
   Google Scholar
• OZBEY N, ORHAN Y, ARAL F, AZEZLI A, MOLVALILAR S, SENCER E: The effects of 'testosterone undecanoate used for the treatment of delayed puberty and hypogonadism on serum glucose, insulin and lipid levels. Istanbul Tip Fakukesi Mecmuasi (1997)60:16–20.
   Google Scholar
• BASARIA S, DOBS AS: Risks versus benefits of testosterone therapy in elderly men. Drugs Aging (1999) 15(2):131–142.
   PubMed Web of Science ®Google Scholar
• WATSON JM, ARMITAGE M: Testosterone hormone replacement and its alternatives. Expert Opin. Ther. Patents (2000) 10(6):859–868.
   Web of Science ®Google Scholar
• ••A thorough review of male hormonereplacement.
   Google Scholar
• DAVIS SR: The therapeutic use of androgens in women. I Steroid Biochem. Mol Biol. (1999) 69(1-6):177–184.
   PubMed Web of Science ®Google Scholar
• FUHRMAN LC JR, MICHNIAK BB, BEHL CR, MALICK AW: Effect of novel penetration enhancers on the transdermal delivery of hydrocortisone: an in vitro species comparison. I Control. Release (1997) 45(29):199–206.
   Google Scholar
• MORGAN TM, REED BL, FINNIN BC: Enhanced skin permeation of sex hormones with novel topical spray vehicles. I Pharm. ScL (1998) 87(10):1213–1218.
   PubMed Web of Science ®Google Scholar
• MORGAN TM, PARR RA, REED BL, FINNIN BC: Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. I Pharm. Sci. (1998) 87(10):1219–1225.
   PubMed Web of Science ®Google Scholar
• DORING GD: Empfärignisverhatung. Georg Thieme Verlag, Stuttgart, Germany (1990):34.
   Google Scholar
• LAHTEENMAKI P, BARDIN CW, ELOMAA K et al. Selection and performance of the levonorgestrel-releasing intrauterine system. Acta Obstetr. Grieco]. Land., Suppl (1997) 76(16):69–74.
   PubMed Web of Science ®Google Scholar
• WILDEMEERSCH D, SCHACHT E: Contraception with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: A pilot study. Eur. Cormacept. Reprod Health Care (2000) 5:234–240.
   PubMedGoogle Scholar
• SUHONEN SP, HOLMSTROM T, ALLONEN HO, LAHTEENMAKI P: Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Feral Steril (1995) 63(2):336–342.
   PubMed Web of Science ®Google Scholar
• ••A basic reference for hormonal implantsand intrauterine systems.
   Google Scholar
• WILDEMEERSCH D, SCHACHT E: Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal woman: a pilot study. Maturitas (2000) 36:63–68.
   PubMed Web of Science ®Google Scholar
• VAN LIEDEKERKE D, GEVERS R, DE SUTTER PH, BOURGAIN C, AMY JJ: Use of levonorgestrel intrauterine device for prevention of endometrial changes induced by tamoxifen. Eur. I Cancer (1998) 34\(Suppl. 4):555–556.
   Google Scholar
• GARDNER FJE, KONJE JC, ABRAMS KR etal.: Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet (2000) 356:1711–1717.
   Google Scholar
• THIERY M: Intrauterine contraception: from silver ring to intrauterine contraceptive implant. Eur. I Obstetr. Cyr]. Reprod. Biol. (2000) 90 (2) :145–152.
   PubMed Web of Science ®Google Scholar
• •A thorough overview over the history of the development of intrauterine systems.
   Google Scholar
• CHEN JH, WU SC, SHAO WQ etal.: The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception (1998) 57(6):371–379.
   Google Scholar
• WEISBERG E, FRASER IS, MISHELL JR DR LACARRA M, DARNEY E JACKANICZ TM: A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception (1999) 59(5):305–310.
   PubMed Web of Science ®Google Scholar
• •A sound evaluation of certain vaginal rings.
   Google Scholar
• RATHBONE MJ, MACMILLAN KL, BUNT CR, BURGGRAAF S: Conceptual and commercially available intravaginal veterinary drug delivery systems. Adv. Drug Del. Rev (1997) 28(3):363–392.
   PubMed Web of Science ®Google Scholar
• NEWTON JR: Vaginal Rings for Contraceptive Use. In: Fertily Control: Update and Trends. Rabe T, Runnebaum B (Eds.) Springer Verlag, (1999):185–194.
   Google Scholar
• WEISBERG E, FRASER IS, LACARRA M et al.: Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception (1999) 59(5):311–318.
   PubMed Web of Science ®Google Scholar
• WOOLFSON AD, ELLIOTT GRE, GILLIGAN CA, PASSMORE CM: Design of an intravaginal ring for the controlled delivery of 17-estradiol as its 3-acetate ester. Control. Rel. (1999) 61(3):319–328.
   PubMed Web of Science ®Google Scholar